Revenue Dynamics YoY (Last Twelve Months): Praxis Corp (PRAX)

The exclusivity of Praxis Precision Medicines (PRAX) developments is ensured by patent protection and strict FDA control. The trailing annual sales growth rate confirms market demand, and its latest parameter stands at -99.90. While the team of neurobiologists strives for a breakthrough in epilepsy therapy, high test volatility and a rapid cash burn rate create significant risks to business stability.
Summary analytical data breakdowns for Praxis Precision Medicines Inc (PRAX)

This metric measures the daily dynamics of annual revenue, identifying hidden degradation or growth in fundamental indicators beyond market noise. For Praxis Precision Medicines (PRAX), the year-over-year revenue change for TTM is critical, as it allows for tracking the burn rate against the risks of CNS development failures, thereby determining overall funding sustainability.